Completion Lymphadenectomy

PROCEDURE2 trials

Sponsors

Saint John's Cancer Institute, University Hospital Tuebingen

Conditions

Melanoma

Unknown Phase

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

CompletedNCT00297895

Saint John's Cancer InstituteMelanoma

Start: 2004-09-30End: 2019-09-30Updated: 2022-05-13

Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node)

CompletedNCT02434107

University Hospital TuebingenMelanoma

Start: 2005-12-31End: 2017-12-31Updated: 2022-12-21

Related Papers

Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma

JAMA Surgery2022-08-0338 citations

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence

Journal for ImmunoTherapy of Cancer2021-10-0116 citations

Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node

Journal of Clinical Oncology2019-09-26236 citations

Final analysis of DECOG-SLT trial: Survival outcomes of complete lymph node dissection in melanoma patients with positive sentinel node.

Journal of Clinical Oncology2018-05-2019 citations

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

New England Journal of Medicine2017-06-071351 citations

Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial.

2016-05-05430 citations